Skip to main content

Table 2 Summary of demographics and anchor variables at Baseline

From: Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray

Parameter ASPIRE I (n = 224) ASPIRE II (n = 227)
Age, years   
Mean (SD) 39.3 (12.91) 40.8 (13.07)
Range 18–64 18–64
Sex, n (%)   
Women 138 (61.6) 136 (59.9)
Men 86 (38.4) 91 (40.1)
QLDS   
Mean (SD) 27.24 (6.40) 26.77 (5.64)
Range 0–34 5–34
MADRS score   
Mean (SD) 41.1 (6.07) 39.7 (5.48)
Range 29–58 29–54
CGI-SS-r, n (%)   
Normal, not at all suicidal 0 0
Questionably suicidal 8 (3.6) 4 (1.8)
Mildly suicidal 17 (7.6) 16 (7.0)
Moderately suicidal 57 (25.6) 68 (30.0)
Markedly suicidal 80 (35.9) 90 (39.6)
Severely suicidal 56 (25.1) 45 (19.8)
Among the most extremely suicidal patients 5 (2.2) 4 (1.8)
CGI-SR-I, n (%)   
No imminent suicide risk 5 (2.2) 3 (1.3)
Minimal imminent suicide risk 12 (5.4) 8 (3.5)
Mild imminent suicide risk 17 (7.6) 18 (7.9)
Moderate imminent suicide risk 57 (25.6) 63 (27.8)
Marked imminent suicide risk 75 (33.6) 80 (35.2)
Severely imminent suicide risk 53 (23.8) 49 (21.6)
Extreme imminent suicide risk 4 (1.8) 6 (2.6)
EQ-VAS   
Mean (SD) 42.0 (24.44) 39.5 (22.62)
Range 0–100 0–95
  1. CGI-SR-I Clinical Global Impression of Imminent Suicide Risk, CGI-SS-r Clinical Global Impression of Severity of Suicidality-Revised, EQ-VAS EuroQol Visual Analog Scale, MADRS Montgomery–Åsberg Depression Rating Scale, QLDS Quality of Life Depression Scale, SD Standard Deviation